Antigen-specific immune therapy (CNP-106) for treatment of generalised myasthenia gravis: rationale and design of first-in-human randomised controlled trial
Antigen-specific immune therapy (CNP-106) for treatment of generalised myasthenia gravis: rationale and design of first-in-human randomised controlled trial
Molly Frey, Derrick McCarthy, Richard J. Nowak, Adam Elhofy et al.
Citations
2 citations
Journal
BMJ Neurology Open
Topics
Myasthenia Gravis and Thymoma
Field-Weighted Citation Impact (FWCI)
0.74
article
Antigen-specific immune therapy (CNP-106) for treatment of generalised myasthenia gravis: rationale and design of first-in-human randomised controlled trial
Molly Frey, Derrick McCarthy, Richard J. Nowak, Adam Elhofy, Stefan Brew
article en
2 citations
Abstract
No abstract available for this paper.
Publication Tag
BMJ Neurology OpenVol. 6(2)
Institutions
Yale University (US), Arie Crown Hebrew Day School (US)